| Primary |
| Drug Use For Unknown Indication |
28.2% |
| Thrombosis Prophylaxis |
15.3% |
| Deep Vein Thrombosis |
10.0% |
| Product Used For Unknown Indication |
8.0% |
| Pulmonary Embolism |
6.6% |
| Drug Exposure During Pregnancy |
6.3% |
| Prophylaxis |
5.7% |
| Embolism Venous |
3.4% |
| Atrial Fibrillation |
2.7% |
| Phlebitis |
1.9% |
| Thrombosis |
1.9% |
| Pain |
1.7% |
| Anticoagulant Therapy |
1.6% |
| Haemodialysis |
1.3% |
| Dialysis |
1.1% |
| Diffuse Large B-cell Lymphoma |
0.9% |
| Thrombophlebitis |
0.9% |
| Vena Cava Thrombosis |
0.9% |
| Knee Arthroplasty |
0.8% |
| Nausea |
0.8% |
|
| Pulmonary Embolism |
18.4% |
| Premature Baby |
16.3% |
| Deep Vein Thrombosis |
7.8% |
| Off Label Use |
7.0% |
| Drug Exposure During Pregnancy |
4.9% |
| Thrombocytopenia |
4.9% |
| Heparin-induced Thrombocytopenia |
4.4% |
| Thrombosis |
4.0% |
| Drug Ineffective |
3.8% |
| Premature Labour |
3.4% |
| Premature Separation Of Placenta |
3.4% |
| Thrombocytosis |
3.2% |
| Thrombosis In Device |
3.2% |
| Maternal Drugs Affecting Foetus |
3.0% |
| Death |
2.3% |
| Small For Dates Baby |
2.3% |
| Haemoglobin Decreased |
2.1% |
| Stillbirth |
1.9% |
| Threatened Labour |
1.9% |
| Underdose |
1.9% |
|
| Secondary |
| Drug Use For Unknown Indication |
31.5% |
| Product Used For Unknown Indication |
11.3% |
| Pulmonary Embolism |
7.8% |
| Prophylaxis |
7.3% |
| Thrombosis Prophylaxis |
6.2% |
| Deep Vein Thrombosis |
5.4% |
| Supraventricular Tachycardia |
3.2% |
| Chronic Obstructive Pulmonary Disease |
3.1% |
| Epilepsy |
3.1% |
| Dermatitis |
2.3% |
| Nausea |
2.3% |
| Pain |
2.3% |
| Abdominal Infection |
2.0% |
| Grand Mal Convulsion |
2.0% |
| Acute Coronary Syndrome |
1.9% |
| Hypertension |
1.9% |
| Constipation |
1.6% |
| Depression |
1.5% |
| Foetal Exposure During Pregnancy |
1.5% |
| Rheumatoid Arthritis |
1.5% |
|
| Toxic Epidermal Necrolysis |
10.7% |
| Premature Baby |
9.4% |
| Thrombocytopenia |
9.4% |
| Premature Separation Of Placenta |
7.5% |
| Pulmonary Embolism |
6.3% |
| Tuberculosis |
5.0% |
| Death |
4.4% |
| Off Label Use |
4.4% |
| Postpartum Haemorrhage |
4.4% |
| Rectal Haemorrhage |
4.4% |
| Deep Vein Thrombosis |
3.8% |
| Dysmorphism |
3.8% |
| Renal Failure Acute |
3.8% |
| Respiratory Failure |
3.8% |
| Thrombosis |
3.8% |
| Haematoma |
3.1% |
| Threatened Labour |
3.1% |
| Toxic Skin Eruption |
3.1% |
| Transient Tachypnoea Of The Newborn |
3.1% |
| Stillbirth |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.4% |
| Drug Use For Unknown Indication |
14.2% |
| Prophylaxis |
9.5% |
| Multiple Myeloma |
7.3% |
| Pain |
6.6% |
| Hypertension |
5.2% |
| Thrombosis Prophylaxis |
4.0% |
| Nausea |
3.6% |
| Pulmonary Embolism |
2.8% |
| Plasma Cell Myeloma |
2.6% |
| Muscle Spasms |
2.3% |
| Anaemia |
2.2% |
| Breast Cancer |
2.1% |
| Hypercalcaemia |
2.0% |
| Arthritis |
1.9% |
| Depression |
1.9% |
| Osteoporosis |
1.9% |
| Thrombosis |
1.9% |
| Deep Vein Thrombosis |
1.7% |
| Non-small Cell Lung Cancer |
1.7% |
|
| Vomiting |
11.6% |
| Pulmonary Embolism |
10.1% |
| Renal Failure Acute |
8.3% |
| Cytolytic Hepatitis |
7.6% |
| Pyrexia |
7.2% |
| Thrombocytopenia |
6.2% |
| General Physical Health Deterioration |
5.4% |
| Sepsis |
5.1% |
| Lung Disorder |
4.7% |
| Weight Decreased |
4.3% |
| Death |
4.0% |
| Thrombosis |
3.3% |
| Deep Vein Thrombosis |
2.9% |
| Pneumonia |
2.9% |
| Renal Failure |
2.9% |
| Septic Shock |
2.9% |
| Weight Increased |
2.9% |
| Condition Aggravated |
2.5% |
| Peripheral Sensory Neuropathy |
2.5% |
| Pleural Effusion |
2.5% |
|
| Interacting |
| Pulmonary Embolism |
37.5% |
| Colorectal Cancer |
25.0% |
| Non-small Cell Lung Cancer |
25.0% |
| Pain |
12.5% |
|
| Haematoma |
25.0% |
| Melaena |
25.0% |
| Rectal Polyp |
25.0% |
| Respiratory Distress |
25.0% |
|
